From the New Yorker, June 4, 2012
Notes and counter notes on cancer research and therapies (and some other stuff you don't have to be interested in...), by Gianmarco Contino, MD
Monday, June 4, 2012
FAILURE AND RESCUE
From the New Yorker, June 4, 2012
Friday, May 18, 2012
Tuesday, April 17, 2012
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Make sure to keep in mind this report from the NEJM next time you think of rational design of cancer therapies.
http://www.nejm.org/doi/full/10.1056/NEJMoa1112824
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
The abscopal effect is a phenomenon in which local radiotherapy is associated with the regression of metastatic cancer at a distance from the irradiated site. The abscopal effect may be mediated by activation of the immune system. Ipilimumab is a monoclonal antibody that inhibits an immunologic checkpoint on T cells, cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4). We report a case of the abscopal effect in a patient with melanoma treated with ipilimumab and radiotherapy. Temporal associations were noted: tumor shrinkage with antibody responses to the cancer–testis antigen NY-ESO-1, changes in peripheral-blood immune cells, and increases in antibody responses to other antigens after radiotherapy. (Funded by the National Institutes of Health and others.)
T-CELL ARMY
Read more at http://www.newyorker.com/reporting/2012/04/23/120423fa_fact_groopman#ixzz1sIutyBzV
Can the body’s immune response help treat cancer?
by Jerome Groopman
Thursday, January 26, 2012
European Institute of Oncology surgical oncologist wins ESSO award
E-cancer
Congratulations to Gianmarco Contino, a surgical oncologist from the European Institute of Oncology, who has been awarded the prestigious ESSO major training award for 2012.
The aim of these very competitive fellowships is to allow keen young surgeons to visit a specialist centre, expand their experience and learn new techniques.
Wednesday, January 25, 2012
Researchers Gather to Discuss Future of Translational Research Education
Inaugural Kantoff-Sang Lecture draws leaders to discuss Harvard’s approach to the evolving challenges of clinical and translational research education
The pace of discovery in the life sciences is breathtaking. Our understanding of human genetics, as well as the chemical and physical interactions of single molecules within cells, has advanced according to Moore’s Law. Meanwhile, critical new insights show how social networks, psychology and behavioral economics impact health.
And yet, there have been painfully few equivalent advances in human health. The drug development system is stalling, health care costs continue to rise unsustainably, and poverty and politics prevent many in the world from achieving even the most basic standards of human health.
Friday, January 20, 2012
Getting Healthcare Social. Time is ready, doctors are not.
Healthcare is a unique kind of "market". Doctors determine demand, doctors deliver offer. Of course they are not totally free: in the best care scenario they have their professional ethics, knowledge, and compassion. However it would be unfair not to acknowledge the role of national budgets, healthcare policies, big and small pharmas, medical device companies, and insurances. Patients are always at the bottom of this complex network, unfortunately not as real players. Drug and healthcare advertisement don't make a patient free to choose about his own health. Considering the relevance of healthcare choices, advertisement is not able to improve patient's awareness, and in a way it distracts patient-doctor relationship from its trustworthy nature. At the same time, entirely delegating choice to the patient by providing tons of information, doesn't help patient's awareness, it just makes him feel alone with his medical condition.
I have no doubt, time has come for a change. Doctors have been bound to the Hippocratic Oath "to give a share of precepts and oral instruction and all the other learning to my sons and to the sons of him who has instructed me and to pupils who have signed the covenant and have taken the oath according to medical law, but to no one else." Thus, medicine has been immune by a true "democratization" process, and doctors need to help this process go in the right direction.
Shared decision making is what we need. Embracing this change will save and strengthen the value of patient-doctor relationship, and minimize most of the deviated influences I wouldn't have liked to list above. Shared decision making means essentially shared medical knowledge, and shared personal and institutional healthcare information.
Medical knowledge has been increasingly spread by some high quality governative and private channels, although bad quality healthcare is what make the most of internet and other media. We need a quality ranking system to help people choose where to learn.
Shared personal and institutional information is the most complex part of the problem. The first issue is privacy. Once this is solved a new issue, we can hardly see at the moment, will be what to make of those information in order to help patients to choose and doctors to deliver better care. At the moment both patients and doctors do not see the enormous potential of embracing this challenge. As a result, investment and commitment of government and academia is poor.
I want to give you a taste of what is the potential of medicine getting social the right way. Doctors know every patient is unique, but rely on the largest studies possible to deliver evidence based medicine, which is the best care for the average patient. This medicine is not up to date with the potential of personalized medicine, and old school trials are getting obsolete. Shared medical information has potential to retrieve new kind of data on best personalized treatment, taking in account actual compliance to the treatment, past medical history, geographic area and in close future genetic determinants. Doctors working in underserved or poor areas, will be able to compare treatment with similar areas around the world. Medicine try to set up the best standard of care by implementing new therapies or devices, which constantly increase prices. Not all the world lives in Massachusetts. It will be able to create communities able to negotiate the price of specific drugs such Herceptin for breast cancer, whose cost are extremely variable depending on insurances and public health/government institutions, but most of the time not accessible to poor areas of the worlds. Examples can extend to infinite. But one thing should be enough to convince you this effort is worth. Shared decision making will build up a medicine that requires doctors to listen to patients and vice versa, and doctors and patients listening among them. This is more relevant to the Hippocratic Oath than it is restricting access to knowledge.
I found some inspiration in:
Dave deBronkart, known as e-patient Dave http://www.youtube.com/watch?v=2vejkD0Rl3o
and Information needs of cancer patients and their organisations
Thursday, January 19, 2012
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors — NEJM
Doctor and Patient: Why Doctors Can't Predict Life Expectancy - NYTimes.com
January 19, 2012, 12:01 AM
Why Doctors Can’t Predict How Long a Patient Will Live
Sunday, January 15, 2012
Processed meat and Pancreatic cancer are linked, one more reason to go veggie.
Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies
background:
methods:
results:
conclusion:
Sunday, January 1, 2012
1) Introduzione al Tumore del Colon-retto
Primo episodio del videolog sul tumore del colon retto. Gli argomenti trattati sono l'epidemiologia, i fattori di rischio, la prevenzione e cenni di terapia. Questo video e' adeguato al pubblico generale e non sostituisce il parere del medico curante cui e' sempre necessario rivolgersi. Spero sia utile a chi vuole o ha bisogno di capire qualcosa in piu' su questa malattia. a presto Gm